Lipid panel
Searched over 200M research papers for "lipid panel"
Summary
10 papers analyzed
These studies suggest that various advanced lipid panel technologies, including NMR ELP assays, LipidSeq, automated lipid panels, UPLC-MS/MS methods, and novel mass spectrometry workflows, improve the accuracy, cost-effectiveness, and diagnostic capabilities for lipid-related disorders and cardiovascular risk assessment.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta19 papers analyzed
Comprehensive Insights on Lipid Panel Testing
Introduction to Lipid Panel Testing
Lipid panel testing is a fundamental tool in assessing cardiovascular health. It typically includes measurements of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and calculated low-density lipoprotein cholesterol (LDL-C). These metrics are crucial for evaluating the risk of atherosclerotic cardiovascular disease (ASCVD) and guiding therapeutic decisions.
Advanced Lipid Panel Assays
Nuclear Magnetic Resonance (NMR) Extended Lipid Panel
The NMR-based Extended Lipid Panel (ELP) is a high-throughput method that measures TC, TG, HDL-C, and apolipoprotein B (apoB) simultaneously. This method has shown excellent agreement with traditional chemical assays, with correlation coefficients ranging from 0.980 to 0.997. The inclusion of apoB, which is a superior marker for lipid-lowering therapy decisions, enhances the clinical utility of the lipid panel.
Fully Automated Lipid Panel
A fully automated lipid panel integrates tests for TC, TG, apolipoprotein A-1, and apoB. This system is designed for high accuracy and cost-effectiveness, with each test costing less than $3.00 per patient. The automation and minimal sample volume requirements make it suitable for both clinical and research settings.
Genetic Insights from Lipid Panels
LipidSeq: Targeted Sequencing for Dyslipidemias
LipidSeq is a targeted sequencing panel designed to study genetic determinants of dyslipidemia. It evaluates 69 genes and 185 single-nucleotide polymorphisms (SNPs) associated with lipid disorders. This panel has been instrumental in diagnosing and improving treatment options for patients with monogenic and polygenic dyslipidemias. Over six years, LipidSeq has identified numerous novel variants and mechanisms underlying lipid disorders.
Next-Generation Sequencing for Monogenic Dyslipidemias
LipidSeq also serves as a next-generation resequencing panel for monogenic dyslipidemias, offering a high detection rate of causative mutations. It provides a focused approach, avoiding incidental findings unrelated to lipid metabolism, thus minimizing ethical concerns.
Point-of-Care and High-Throughput Lipid Testing
Lipidest: Portable Lipid Profile Screening
Lipidest is a novel diagnostic technology that uses a portable spinning disc and an office scanner to quantify lipid panels from finger-prick blood. This method eliminates the need for sample preparation and complex devices, making it ideal for resource-constrained settings. It offers a user-friendly, cost-effective solution for timely cardiovascular health monitoring.
High-Throughput LC-MS/MS for Lipidomics
A high-throughput LC-MS/MS approach enables comprehensive lipid profiling across 26 lipid subclasses. This method provides robust quantification of lipid species, facilitating detailed circulatory lipid phenotyping in clinical research. It offers high precision and accuracy, making it a valuable tool for metabolic health studies.
Advanced Lipid Testing and Cardiovascular Risk
Spherical Coordinates for Cardiovascular Risk Prediction
Transforming lipid panel data into spherical coordinates can enhance cardiovascular risk prediction. This method bypasses traditional LDL-C calculations and provides a novel phenotypic classification system. It has shown greater prognostic ability than LDL-C and can classify individuals into distinct phenotypes associated with specific clinical features.
Advanced Lipoprotein Particle Analysis
Advanced lipid testing includes assays that subfractionate lipoprotein particles based on size, density, and charge. Techniques such as vertical auto profile (VAP), NMR, and mass spectrometry offer additional insights into ASCVD risk and therapeutic options. However, these advanced tests are not yet uniformly recommended in clinical guidelines.
Conclusion
Lipid panel testing remains a cornerstone in cardiovascular risk assessment. Advances in NMR, automated systems, genetic sequencing, and high-throughput technologies are enhancing the accuracy, efficiency, and clinical utility of lipid measurements. These innovations are paving the way for more personalized and effective management of dyslipidemias and cardiovascular health.
Sources and full results
Most relevant research papers on this topic
